Carlos L. Arteaga - Publications

Vanderbilt University, Nashville, TN 
Cell Biology, Oncology, Molecular Biology

63 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Zonneville J, Safina A, Truskinovsky AM, Arteaga CL, Bakin AV. TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. Bmc Cancer. 18: 670. PMID 29921235 DOI: 10.1186/s12885-018-4587-z  0.6
2017 Limoge M, Safina A, Truskinovsky AM, Aljahdali I, Zonneville J, Gruevski A, Arteaga CL, Bakin AV. Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget. 8: 61969-61981. PMID 28977919 DOI: 10.18632/oncotarget.18755  0.6
2017 Limoge M, Safina A, Truskinovsky AM, Aljahdali I, Zonneville J, Gruevski A, Arteaga CL, Bakin AV. Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget. PMID 28706147 DOI: 10.18632/oncotarget.18755  0.6
2016 Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer. Breast Cancer Research and Treatment. PMID 27771839 DOI: 10.1007/s10549-016-4011-9  0.6
2016 Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, ... ... Arteaga CL, et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine. 8: 334ra53. PMID 27075627 DOI: 10.1126/scitranslmed.aad3001  0.6
2015 Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population. Cancer Research. PMID 26676751 DOI: 10.1158/0008-5472.CAN-15-1640-T  0.6
2015 Young CD, Arteaga CL, Cook RS. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Breast Cancer Research : Bcr. 17: 148. PMID 26637440 DOI: 10.1186/s13058-015-0656-2  0.6
2015 Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, ... ... Arteaga CL, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/mcp.M115.049783  0.6
2015 Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC. Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. Journal of Biomedical Optics. 20: 26004. PMID 25700233 DOI: 10.1117/1.JBO.20.2.026004  0.6
2015 Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Research. 75: 405-14. PMID 25480943 DOI: 10.1158/0008-5472.CAN-14-2475  0.6
2015 Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE. Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 119-28. PMID 25034624 DOI: 10.1007/s11307-014-0770-z  0.6
2014 Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/Oncology and Stem Cell Therapy. 7: 142-8. PMID 25467032 DOI: 10.1016/j.hemonc.2014.09.007  0.6
2014 Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research : Bcr. 16: 406. PMID 25103565 DOI: 10.1186/s13058-014-0406-x  0.6
2014 Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Research. 74: 5184-94. PMID 25100563 DOI: 10.1158/0008-5472.CAN-14-0663  0.6
2014 McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. Biomedical Optics Express. 5: 2247-61. PMID 25071962 DOI: 10.1364/BOE.5.002247  0.6
2014 Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, ... ... Arteaga CL, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. The Oncologist. 19: 616-22. PMID 24797823 DOI: 10.1634/theoncologist.2014-0011  0.6
2014 Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1202-9. PMID 24663045 DOI: 10.1200/JCO.2013.54.0518  0.6
2014 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 25: 282-303. PMID 24651011 DOI: 10.1016/j.ccr.2014.02.025  0.6
2014 Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A. Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. Journal of Biomedical Optics. 19: 025001. PMID 24496495 DOI: 10.1117/1.JBO.19.2.025001  0.6
2014 Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1757-67. PMID 24398047 DOI: 10.1158/1078-0432.CCR-13-2332  0.6
2014 Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, ... ... Arteaga CL, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discovery. 4: 232-45. PMID 24356096 DOI: 10.1158/2159-8290.CD-13-0286  0.6
2013 Hanker AB, Cook RS, Arteaga CL. Mouse models and anti-HER2 therapies. Oncotarget. 4: 1866-7. PMID 24272818  0.6
2013 Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Research. 73: 6164-74. PMID 24130112 DOI: 10.1158/0008-5472.CAN-13-0527  0.6
2013 Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, et al. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. The Journal of Clinical Investigation. 123: 4329-43. PMID 23999432 DOI: 10.1172/JCI66764  0.6
2013 Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5390-401. PMID 23948973 DOI: 10.1158/1078-0432.CCR-13-1038  0.6
2013 Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 14372-7. PMID 23940356 DOI: 10.1073/pnas.1303204110  0.6
2013 Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, ... ... Arteaga CL, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Research. 73: 6024-35. PMID 23928993 DOI: 10.1158/0008-5472.CAN-13-1198  0.6
2013 Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Research. 73: 6013-23. PMID 23918797 DOI: 10.1158/0008-5472.CAN-13-1191  0.6
2013 Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3703-13. PMID 23697991 DOI: 10.1158/1078-0432.CCR-13-0623  0.6
2013 Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Research. 73: 4075-85. PMID 23633485 DOI: 10.1158/0008-5472.CAN-12-4579  0.6
2013 Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. The Journal of Clinical Investigation. 123: 1348-58. PMID 23391723 DOI: 10.1172/JCI65416  0.6
2013 Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 610-9. PMID 23224399 DOI: 10.1158/1078-0432.CCR-12-2024  0.6
2013 Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Research. 73: 1190-200. PMID 23204226 DOI: 10.1158/0008-5472.CAN-12-2440  0.6
2012 Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, ... ... Arteaga CL, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine. 18: 1052-9. PMID 22683778 DOI: 10.1038/nm.2795  0.6
2012 Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Research. 72: 3228-37. PMID 22552284 DOI: 10.1158/0008-5472.CAN-11-3747  0.6
2012 Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proceedings of the National Academy of Sciences of the United States of America. 109: 221-6. PMID 22178756 DOI: 10.1073/pnas.1115802109  0.6
2012 Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors Proceedings of the National Academy of Sciences of the United States of America. 109: 2718-2723. PMID 21368164 DOI: 10.1073/pnas.1018001108  0.6
2011 Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2: 1314-1319. PMID 22248929  0.6
2011 Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, ... ... Arteaga CL, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discovery. 1: 352-65. PMID 22145099 DOI: 10.1158/2159-8290.CD-11-0106  0.6
2011 Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Research. 71: 6773-84. PMID 21908557 DOI: 10.1158/0008-5472.CAN-11-1295  0.6
2011 Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Research. 71: 5965-75. PMID 21775521 DOI: 10.1158/0008-5472.CAN-11-0445  0.6
2011 Chow A, Arteaga CL, Wang SE. When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene. Journal of Mammary Gland Biology and Neoplasia. 16: 81-8. PMID 21590373 DOI: 10.1007/s10911-011-9206-4  0.6
2011 Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis Cancer Research. 71: 3941-3951. PMID 21482676 DOI: 10.1158/0008-5472.CAN-10-3775  0.6
2011 Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 108: 5021-6. PMID 21385943 DOI: 10.1073/pnas.1016140108  0.6
2011 Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, ... ... Arteaga CL, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research. 71: 1871-82. PMID 21324925 DOI: 10.1158/0008-5472.CAN-10-1872  0.6
2010 Rejniak KA, Wang SE, Bryce NS, Chang H, Parvin B, Jourquin J, Estrada L, Gray JW, Arteaga CL, Weaver AM, Quaranta V, Anderson AR. Linking changes in epithelial morphogenesis to cancer mutations using computational modeling. Plos Computational Biology. 6. PMID 20865159 DOI: 10.1371/journal.pcbi.1000900  0.6
2010 Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Research : Bcr. 12: R41. PMID 20576088 DOI: 10.1186/bcr2595  0.6
2009 Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7266-76. PMID 19934303 DOI: 10.1158/1078-0432.CCR-09-1665  0.6
2009 Anderson AR, Hassanein M, Branch KM, Lu J, Lobdell NA, Maier J, Basanta D, Weidow B, Narasanna A, Arteaga CL, Reynolds AB, Quaranta V, Estrada L, Weaver AM. Microenvironmental independence associated with tumor progression. Cancer Research. 69: 8797-806. PMID 19887618 DOI: 10.1158/0008-5472.CAN-09-0437  0.6
2009 Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S. Brain metastasis: opportunities in basic and translational research. Cancer Research. 69: 6015-20. PMID 19638593 DOI: 10.1158/0008-5472.CAN-08-4347  0.6
2009 Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4712-21. PMID 19584166 DOI: 10.1158/1078-0432.CCR-08-2635  0.6
2009 Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL, Segall JE. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3733-9. PMID 19458057 DOI: 10.1158/1078-0432.CCR-08-2163  0.6
2009 Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Research. 69: 4192-201. PMID 19435893 DOI: 10.1158/0008-5472.CAN-09-0042  0.6
2008 Criswell TL, Dumont N, Barnett JV, Arteaga CL. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Research. 68: 7304-12. PMID 18794117 DOI: 10.1158/0008-5472.CAN-07-6777  1
2005 Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 937s-43s. PMID 15701890  1
2004 Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. The Journal of Biological Chemistry. 279: 24505-13. PMID 15044465 DOI: 10.1074/jbc.M400081200  1
2003 Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 3: 531-6. PMID 12842082  1
2003 Dumont N, Arteaga CL. A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochemical and Biophysical Research Communications. 301: 108-12. PMID 12535648  1
2003 Dumont N, Bakin AV, Arteaga CL. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. The Journal of Biological Chemistry. 278: 3275-85. PMID 12421823 DOI: 10.1074/jbc.M204623200  0.6
2002 Dumont N, Arteaga CL. The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFbeta. Differentiation; Research in Biological Diversity. 70: 574-82. PMID 12492498  1
2002 Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. The Journal of Clinical Investigation. 109: 1551-9. PMID 12070302 DOI: 10.1172/JCI15234  0.6
2001 McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. International Journal of Cancer. 91: 76-82. PMID 11149423 DOI: 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8  0.6
2000 Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Research : Bcr. 2: 125-32. PMID 11250702  1
Show low-probability matches.